Effect of aprepitant for nausea and vomiting during Paclitaxel + Carboplatin (TC) therapy

Effect of aprepitant for nausea and vomiting during Paclitaxel + Carboplatin (TC) therapy - Effect of aprepitant for nausea and vomiting during TC therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012500

Enrollment

Registered

2013-12-10

Start date

2011-01-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecologic malignancy

Interventions

Group A: 1st course 5HT3 receptor antagonist + dexamethasone iv 2nd course 5HT3 receptor antagonist + dexamethasone iv + aprepitant p.o. Group B: 1st course 5HT3 receptor antagonist + de

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.The patientwith gynecological malignancy that TC is taken as first line chemotherapy. 2.PS<2

Exclusion criteria

Exclusion criteria: 1.PS>=2 2.the patient who were judged as inadequacy

Design outcomes

Primary

Measure	Time frame
effect of antiemesis	—

Countries

Japan

Contacts

Public ContactMasanori Kanemura

Osaka Medical College Department of Obstetrics and Gynecology

gyn044@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026